Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating KB707, a genetically modified herpes simplex type 1 virus designed to stimulate the immune system against tumors, in adults with advanced or metastatic solid tumors, including melanoma. This Phase 12, open-label study aims to assess the safety, tolerability, preliminary efficacy, and immune effects of KB707 alone and in combination with immune checkpoint inhibitors in subjects who have progressed on or cannot tolerate standard therapies. Participants in initial dose escalation and expansion cohorts receive intratumoral KB707 injections approximately every three weeks. Later cohorts evaluate KB707 given biweekly combined with either Opdualag, a dual immune checkpoint inhibitor, or Keytruda, an immune checkpoint inhibitor dosed every 4 or 6 weeks respectively. Treatment continues until disease progression, unacceptable side effects, or other study or participant decisions. Throughout the study, subjects undergo assessments for adverse events, serious adverse events, and overall response rate up to 36 months. Researchers monitor safety, tolerability, and tumor response while participants receive regular intratumoral injections and immune therapies. The study includes ongoing follow-up to evaluate treatment effects and participant health over an extended period.
Actively Recruiting
Researchers are evaluating KB803, an ophthalmic suspension containing a modified herpes simplex virus expressing human collagen VII protein, in patients with dystrophic epidermolysis bullosa DEB who experience recurrent corneal abrasions. This Phase 3, double-blind, randomized, placebo-controlled crossover study aims to assess the safety and effectiveness of KB803 compared to a matched placebo in both children and adults with DEB. The study is sponsored by Krystal Biotech, Inc. Participants who have been in the Sponsors natural history study for at least 12 weeks and meet other criteria will be randomly assigned to receive either KB803 or placebo eye drops three times a week for the first 12 weeks. Then, they will switch to the alternate treatment for another 12 weeks. The eye treatments are given at home by a trained person, with monitoring by the study team. During the 24-week study, researchers will monitor safety and tolerability, track the frequency of corneal abrasion symptoms, and assess eye pain. Participants or their guardians will keep weekly symptom diaries and complete monthly questionnaires about symptoms and disease severity. Study staff will regularly check for any side effects or changes in treatment. The total participation lasts 24 weeks with ongoing safety and symptom evaluations.
Actively Recruiting
Researchers are conducting a Phase 3, multicenter, open-label study to evaluate the pharmacokinetics and safety of dupilumab in children and adolescents aged 6 months to under 18 years who have prurigo nodularis. This condition requires participants to have a clinical diagnosis with specific lesion and itch severity criteria to be included. The study aims to better understand how dupilumab behaves in the body and its safety profile in this population. Participants will receive dupilumab administered subcutaneously, with dosing based on their weight and age. The study includes three distinct periods a screening period lasting 2 to 4 weeks, a treatment period of 24 weeks during which dupilumab is given, and a post-intervention follow-up period lasting 16 weeks. The total participation time is approximately 42 to 44 weeks, and there will be six planned study visits for each participant. During the study, participants and caregivers will complete daily symptom e-diaries to track itch severity and other symptoms. Researchers will monitor the concentration of dupilumab in the blood from Day 1 through Week 40, as well as the incidence of any treatment-related adverse events and the development of anti-drug antibodies. Safety and effectiveness will be assessed throughout the treatment and follow-up periods, ensuring thorough observation over the entire study duration.
Actively Recruiting
Researchers are conducting a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SD-101-6.0 cream compared to a placebo in treating wounds in patients with Epidermolysis Bullosa EB. The study includes patients diagnosed with Simplex, Recessive Dystrophic, or Junctional non-Herlitz JEB-nH EB, aged between 1 month and 12 years at the time of enrollment. This trial aims to assess wound healing and symptom relief in this pediatric population. Participants will be randomly assigned to receive either SD-101-6.0 cream or a placebo cream without allantoin. The topical treatment will be applied once daily over the entire body for 60 days. A target wound, present for at least 21 days and measuring between 10 and 50 cm8, will be selected for assessment. The study involves four site visits over two months, during which wound healing and itching will be evaluated. After completing this period, participants may continue using SD-101-6.0 cream at home in an open-label extension. During the study, participants will have their target wound measured and photographed at baseline and follow-up visits at approximately 14, 30, and 60 days. The ARANZ SilhouetteStar132 device will be used to measure the wound until it is closed. Assessments will also include body surface area affected and itching levels. Minimal assessments occur at the four visits, and the study drug and placebo require no special storage. The total participation time is about two months, with ongoing access to the study drug possible afterward.
Actively Recruiting
This research aims to evaluate the long-term safety of gene therapy products developed by Krystal Biotech, Inc. These products share a common herpes simplex virus type 1 HSV-1 backbone and have been given to participants in previous studies. The study focuses on participants with conditions such as dystrophic epidermolysis bullosa, including its recessive and dominant forms, who have received at least one dose of the investigational gene therapy. The study is observational and involves annual follow-up visits for up to five years after the participants last visit in their previous treatment study. These follow-up visits are designed to monitor and identify any delayed adverse events and to better understand how long the gene therapy products persist in the body. No new treatments are given during this follow-up period. Participants will be asked to provide consent and will undergo yearly safety assessments to track serious adverse events over five years. The study collects data on the participants health and any side effects that may appear long after the initial gene therapy treatment. This long-term monitoring helps ensure ongoing safety and provides valuable information about the gene therapy products.